Biomarkers of Molecular Risk in Smokers

CompletedOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Smoking Cessation
Interventions
BEHAVIORAL

Vignette, questionnaires and Saliva Samples

The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.

BEHAVIORAL

Urine Collection, Smoking cessation treatment

Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Vanderbilt University School of Medicine

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00598143 - Biomarkers of Molecular Risk in Smokers | Biotech Hunter | Biotech Hunter